Literature DB >> 27251683

Association between white blood cell count and non-alcoholic fatty liver disease in urban Han Chinese: a prospective cohort study.

Shukang Wang1, Chengqi Zhang2, Guang Zhang2, Zhongshang Yuan1, Yanxun Liu1, Lijie Ding1, Xiubin Sun1, Hongying Jia3, Fuzhong Xue1.   

Abstract

OBJECTIVES: The white blood cell (WBC) count is a simple and convenient marker of inflammation for use in medical practice; however, its association with non-alcoholic fatty liver disease (NAFLD) has not been determined. We examined the relationship between WBC and NAFLD to provide a convenient and useful marker for the prediction of NAFLD.
SETTING: A longitudinal cohort participating in a large health check-up programme for the Chinese population was selected and followed up from 2005 to 2011. PARTICIPANTS: A total of 21 307 male and female participants without NAFLD who underwent health check-ups at least twice between 2005 and 2011 were included in this study. 15 201 participants (7286 men and 7915 women) were eligible for inclusion.
RESULTS: The baseline distribution of age, WBC, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting plasma glucose (FPG), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), serum total protein (TP), albumin (ALB) and globin (GLO) and the prevalence of males, hypertension, hyperglycaemia, smoking and regular exercise were significantly different between the incident NAFLD and non-NAFLD groups (p<0.05). Cox proportional hazards regression analysis was performed to estimate the HRs and 95% CIs of WBC, which predicted the occurrence of NAFLD. Compared with the lowest WBC quartile (Q1), the HRs and 95% CIs of the other WBC quartiles (Q2, Q3 and Q4) for incident NAFLD were 1.090 (0.978 to 1.215), 1.174 (1.055 to 1.305) and 1.152 (1.035 to 1.281), respectively, after adjusting for age, gender, smoking, regular exercise, BMI, hypertension, hyperglycaemia, TC, TG, HDL-C, LDL-C, ALB and GLO.
CONCLUSIONS: Our study clearly showed that WBC count was a significant factor associated with incident NAFLD in Han Chinese. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Chinese adults; Non-alcoholic Fatty Liver Disease (NAFLD); White blood cell (WBC); longitudinal cohort study

Mesh:

Substances:

Year:  2016        PMID: 27251683      PMCID: PMC4893843          DOI: 10.1136/bmjopen-2015-010342

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


This was a longitudinal rather than a cross-sectional study of a cohort selected from a large health check-up programme in a Chinese population and followed up from 2005 to 2011. An association between white blood cell (WBC) count and non-alcoholic fatty liver disease (NAFLD) was confirmed: WBC count can be regarded as an independent predictor of NAFLD. This finding cannot be easily extended to the general population, since the subjects were selected from a routine health check-up programme. Ultrasonography is inadequate for diagnosing NAFLD, and is less accurate than the gold standard biopsy. The severity of the NAFLD was not clearly defined in the health check-up data.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological condition that ranges from simple steatosis to steatohepatitis, fibrosis or cirrhosis of the liver.1 It is a very common liver disease in Europe2 and the USA,3 affecting more than 30% of the general population.4 5 The prevalence of NAFLD is also rising rapidly in Asia and China6 7 because of economic development and changes in lifestyle, having increased in China from less than 10% of the general population in China in the 1990s to approximately 20% in 2013.8 Studies have shown that NAFLD can progress to more severe liver diseases, such as hepatocellular carcinoma and liver failure,9 10 thus increasing liver-related mortality and morbidity in the population.11 Furthermore, it is associated with metabolic diseases12 and significantly increases the risk of cardiovascular disease (CVD)13 and type 2 diabetes.14 NAFLD has become one of the most important public health problems worldwide.15 Various inflammatory markers, including C-reactive protein (CRP),16 interleukin-6 (IL-6),17–19 tumour necrosis factor-α (TNF-α)20 and serum IgA level,21 have also been associated with NAFLD. However, to date, only one cross-sectional study with Korean adults has shown a significant association between white blood cell (WBC) count and NAFLD,22 and it is difficult to determine the temporal relationship between an elevated WBC count and the incidence of NAFLD. Cohort studies should be conducted to confirm the temporal relationship between WBC level and incident NAFLD. Moreover, the WBC count is a simple, readily available and inexpensive marker of inflammation for use in medical practice, and has become an important predictor of infectious diseases and of CVD, diabetes23 and metabolic syndrome (MS).24 We therefore conducted a large-scale health assessment-based longitudinal cohort study in an urban Han Chinese population to determine the relationship between WBC count and NAFLD. The findings from such a study may indicate a convenient and useful marker for the further risk appraisal of NAFLD.

Materials and methods

Study population and cohort design

The subjects in our longitudinal cohort were selected from a routine health check-up system based in the Center for Health Management of Shandong Provincial QianFoShan Hospital and Shandong Provincial Hospital. A total of 21 307 male and female participants without NAFLD who visited the health check-up system at least twice between 2005 and 2011 were included. Questions about alcohol intake included the type of alcohol consumed, the frequency of alcohol consumption per week and the usual amount per day (≥20 g/day). Alcohol intake was further coded as an ordered categorical variable as follows: 0, never; 1, seldom; 2, often, wine; 3, often, beer; 4, often, Chinese spirits; and 5, often, mixed/all types. Persons with a value above 1 were considered regular alcohol users. Subjects with regular alcohol intake (n=4774) were excluded as were 538 subjects with a positive serological marker for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb) or a history of chronic liver disease. Additionally, subjects with WBC counts <4.00 or >10.00 cells 109/L were excluded to eliminate any patients with severe infection. Because some participants may have met more than one exclusion criterion, the total number of participants who were eligible for this study was 15 201. This study was approved by the Ethics Committee of the School of Public Health, Shandong University. Written informed consent was obtained from all participants.

Investigation and measurements

During baseline investigations and follow-up, trained interviewers administered a standardised questionnaire to obtain information on age, sex, smoking status and regular exercise. After an overnight fast of at least 12 hours, all subjects underwent a standardised medical examination that included routine anthropometric, clinical and laboratory tests. The anthropometric measurements involved height, weight and blood pressure (BP). Two BP values were taken 5–15 min apart on the right arm by trained examiners. Height and weight were measured after the participants had removed their shoes, heavy clothing and belts. Body mass index (BMI) was calculated as weight (kg)/height2 (m) and was used as an estimate of obesity. Laboratory tests included triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), serum total protein (TP), albumin (ALB) and globin (GLO). All participants also underwent abdominal B-mode ultrasonography.

Definitions of NAFLD, hypertension and hyperglycaemia

In accordance with the revised definition and treatment guidelines for NAFLD issued by the Chinese Hepatology Association in February 2006,25 NAFLD was diagnosed by abdominal ultrasonography that revealed a bright liver and a diffusely echogenic change in the liver parenchyma. Participants diagnosed with alcoholic fatty liver disease, infectious viral hepatitis (HBsAg or HCVAb positive) and other causes of steatosis were excluded. The presence of hypertension was defined as SBP ≥140 mm Hg and diastolic BP (DBP) ≥90 mm Hg, or had SBP ≥140 mm Hg or diastolic BP (DBP) ≥90 mm Hg or a previous diagnosis. The presence of hyperglycaemia was defined as fasting plasma glucose (FPG) ≥6.1 mmol/L or 2-hour post-prandial glucose (PG) ≥7.8 mmol/L or a previous diagnosis.

Statistical analysis

Multiple imputations were performed to account for missing values. Because the imputation method depends on the patterns of the missing data and the types of the imputed variables, without loss of generality, the Markov chain Monte Carlo (MCMC) method provided by the MI procedure of SAS was used.26 Most variables had less than 2% missing observations before imputation, except for smoking and physical activity which had less than 10% missing values. Descriptive statistics were generated for all baseline characteristics according to gender and incident NAFLD or no incident NAFLD. Continuous variables were expressed as the mean and SD (mean±SD), or median (quartile range) based on whether their distribution was normal or skewed as judged by histogram. A two-sample t-test and Wilcoxon rank sum test were used to determine the group difference. Categorical variables were expressed as percentages, and χ2 tests were used to determine the difference for categorical data. Additionally, WBC (cells 109/L) were further categorised separately into quartiles: Q1: WBC <5.35, Q2: 5.35 ≤WBC <6.20, Q3: 6.20 ≤WBC <7.14, and Q4: WBC ≥7.14. The F test or Kruskal-Wallis test was used to compare differences between WBC quartiles. LSD tests were used for multiple comparisons of continuous variables, and the Bonferroni correction was used for multiple comparisons of categorical variables. Cox proportional hazards regression analysis was performed to estimate the HRs and 95% CIs of WBC, which predicted the occurrence of NAFLD. We constructed three Cox proportional hazards regression models by adjusting different confounding factors, including age, gender, smoking, regular exercise, BMI, hypertension, hyperglycaemia, TC, TG, HDL-C, LDL-C, ALB and GLO at baseline. SAS V.9.1.3 (SAS Institute, Cary, North Carolina, USA) and SPSS (V.20.0) were used to perform all statistical analyses.

Results

A total of 15 201 subjects (7286 men and 7915 women) were included in this study. The baseline distributions of age, WBC, BMI, SBP, DBP, FPG, TC, TG, HDL-C, LDL-C, TP, ALB and GLO by gender; the prevalence of hypertension, hyperglycaemia, smoking and regular exercise; and comparisons between males and females are summarised in table 1. The mean age was 45.49±16.49 years in males and 40.60±13.00 years in females. All other variables except TC were significantly different between males and females (p<0.05).
Table 1

Baseline characteristics according to gender

CharacteristicsMales (n=7286)Females (n=7915)Total (n=15 201)
Age45.49±16.4940.60±13.00*42.95±14.98
WBC count (109/L)6.47±1.286.19±1.25*6.32±1.28
BMI (kg/m2)24.33±2.9222.80±3.19*23.53±3.12
SBP (mm Hg)126.68±18.20115.74±17.96*120.98±18.88
DBP (mm Hg)73.77±10.9069.20±10.48*71.39±10.93
FPG (mmol/L)5.13±1.064.89±0.83*5.01±0.95
TC (mmol/L)4.90±0.904.89±0.974.90±0.94
TG (mmol/L)1.16 (0.90)0.88 (0.71)*1.01 (0.83)
HDL-C (mmol/L)1.25 (0.39)1.45 (0.43)*1.35 (0.44)
TP (g/L)73.75±4.3573.91±4.25*73.83±4.30
ALB (g/L)46.80±2.5345.93±2.49*46.35±2.54
GLO (g/L)26.95±3.9827.97±3.95*27.48±4.00
LDL-C (mmol/L)2.85±0.712.70±0.74*2.77±0.73
Hypertension (%)1892 (26.0)979 (12.4)*2871 (18.9)
Hyperglycaemia (%)720 (9.9)390 (4.9)*1110 (7.3)
Current smoker (%)2153 (29.5)36 (0.5)*2189 (14.4)
Regular exercise (%)2953 (40.5)1759 (22.2)*4712 (31)

*p<0.05, comparison between males and females.

ALB, albumin; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; GLO, globin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; TP, serum total protein; WBC, white blood cell count.

Baseline characteristics according to gender *p<0.05, comparison between males and females. ALB, albumin; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; GLO, globin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; TP, serum total protein; WBC, white blood cell count. The baseline characteristics of the subjects according to WBC quartile are shown in table 2. The mean values of age, BMI, SBP, DBP, FPG, TC, TG, LDL-C, TP and GLO and the prevalence of hypertension, hyperglycaemia and smoking were highest in the fourth WBC quartile, in contrast to HDL-cholesterol which was lowest in the fourth WBC quartile. Significant differences were found for the other characteristics except for regular exercise and ALB among the different WBC quartiles (p<0.05). Significant differences were found between various WBC quartiles for BMI, SBP, DBP, FPG, TG, HDL-C, LDL-C, TP, GLO and hypertension (p<0.05). Significant differences for age and TC were found between Q1 and Q3 or Q4, and between Q2 and Q4. Significant differences for hyperglycaemia and smoking were found between Q1 and Q2, Q3 or Q4, and between Q2 and Q4.
Table 2

Comparison of baseline characteristics according to WBC quartile

WBC quartiles
CharacteristicsQ1Q2Q3Q4p Value
N (%)3769382538093798
Age42.33±14.3442.79±15.0243.12±14.8643.54±15.640.004
BMI (kg/m2)22.78±2.8923.35±3.1023.81±3.1124.18±3.19<0.001
SBP (mm Hg)117.73±17.48120.44±18.64121.86±18.94123.88±19.86<0.001
DBP (mm Hg)69.49±10.4671.13±10.7572.00±10.9472.92±11.25<0.001
FPG (mmol/L)4.91±0.814.98±0.935.04±0.985.10±1.06<0.001
TC (mmol/L)4.84±0.944.88±0.944.92±0.934.94±0.94<0.001
TG (mmol/L)0.86 (0.67)0.97 (0.80)1.06 (0.82)1.19 (0.94)<0.001
HDL-C (mmol/L)1.41 (0.43)1.36 (0.44)1.33 (0.43)1.29 (0.43)<0.001
LDL-C (mmol/L)2.69±0.722.76±0.732.80±0.722.85±0.73<0.001
TP (g/L)73.38±4.2473.74±4.2373.96±4.2974.25±4.38<0.001
ALB (g/L)46.28±2.5446.36±2.5646.38±2.4646.38±2.620.287
GLO (g/L)27.10±3.9227.38±4.0127.58±4.0127.87±4.01<0.001
Hypertension (%)539 (14.3)683 (17.9)772 (20.3)877 (23.1)<0.001
Hyperglycaemia (%)197 (5.2)263 (6.9)298 (7.8)352 (9.3)<0.001
Current smoker (%)372 (9.9)481 (12.6)555 (14.6)781 (20.6)<0.001
Regular exercise (%)1169 (31.0)1194 (31.2)1197 (31.4)1152 (30.3)0.839

Q1: WBC <5.35; Q2: 5.35 ≤WBC <6.20; Q3: 6.20 ≤WBC <7.14; Q4: WBC ≥7.14 cells×109/L.

ALB, albumin; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; GLO, globin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; TP, serum total protein; WBC, white blood cell count.

Comparison of baseline characteristics according to WBC quartile Q1: WBC <5.35; Q2: 5.35 ≤WBC <6.20; Q3: 6.20 ≤WBC <7.14; Q4: WBC ≥7.14 cells×109/L. ALB, albumin; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; GLO, globin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; TP, serum total protein; WBC, white blood cell count. Table 3 shows the baseline distributions of age, WBC, BMI, SBP, DBP, FPG, TC, TG, HDL-C, LDL-C, TP, ALB and GLO and the prevalence of males, hypertension, hyperglycaemia, smoking and regular exercise according to NAFLD status during follow-up. All variables were significantly different between incident NAFLD and non-NAFLD groups, and the averages of the other characteristics in the NAFLD group (except HDL-C and ALB) were significantly higher than those in the non-NAFLD group (p<0.05). online supplementary table S1 shows the baseline characteristics according to NAFLD status and are grouped by gender.
Table 3

Baseline characteristics according to NAFLD status

CharacteristicsNAFLD (n=3376)Non-NAFLD (n=11 825)
Age48.89±15.4541.25±14.40*
Male (%)2070 (61.3)5216 (44.1)*
WBC count (cells×109/L)6.53±1.276.26±1.27*
BMI (kg/m2)25.19±2.9923.06±2.99*
SBP (mm Hg)128.80±19.73118.75±18.02*
DBP (mm Hg)75.10±11.2870.33±10.59*
FPG (mmol/L)5.22±1.034.95±0.92*
TC (mmol/L)5.14±0.974.83±0.92*
TG (mmol/L)1.31 (0.97)0.93 (0.74)*
HDL-C (mmol/L)1.29 (0.43)1.36 (0.43)*
LDL-C (mmol/L)2.98±0.742.71±0.71*
TP (g/L)74.09±4.3273.76±4.29*
ALB (g/L)46.18±2.5746.40±2.53*
GLO (g/L)27.90±4.0927.36±3.96*
Hypertension (%)1154 (34.2)1717 (14.5)*
Hyperglycaemia (%)391 (11.6)719 (6.1)*
Current smoker (%)634 (18.8)1555 (13.2)*
Regular exercise (%)1286 (38.1)3426 (29.0)*

*p<0.05, comparison between NAFLD and non-NAFLD.

ALB, albumin; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; GLO, globin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NAFLD, non-alcoholic fatty liver disease; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; TP, serum total protein; WBC, white blood cell count.

Baseline characteristics according to NAFLD status *p<0.05, comparison between NAFLD and non-NAFLD. ALB, albumin; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; GLO, globin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NAFLD, non-alcoholic fatty liver disease; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; TP, serum total protein; WBC, white blood cell count. Table 4 shows the HRs (95% CIs) of WBC as the independent variable in different Cox proportional hazards models. In the unadjusted model, compared with the lowest WBC quartile (Q1), the HRs and 95% CIs of the other WBC quartiles (Q2, Q3 and Q4) in the NAFLD group were 1.310 (1.180 to 1.454), 1.511 (1.365 to 1.673) and 1.654 (1.497 to 1.828), respectively. In the first model, after adjusting for age and gender, compared with the lowest WBC quartile (Q1), the HRs and 95% CIs of the other WBC quartiles (Q2, Q3 and Q4) in the NAFLD group were 1.241 (1.118 to 1.378), 1.427 (1.289 to 1.580) and 1.507 (1.363 to 1.666), respectively, and age and gender were significant variables. In the second model, after adjusting for age, gender, smoking and regular exercise, compared with the lowest WBC quartile (Q1), the HRs and 95% CIs of the other WBC quartiles (Q2, Q3 and Q4) in the NAFLD group were 1.243 (1.116 to 1.384), 1.440 (1.296 to 1.600) and 1.558 (1.404 to 1.729), respectively, and age, gender and regular exercise (not smoking) were significant variables. In the third model, after adjusting for age, gender, smoking, regular exercise, BMI, hypertension, hyperglycaemia, TC, TG, HDL-C, LDL-C, ALB and GLO compared with the lowest WBC quartile (Q1), the HRs and 95% CIs of the other WBC quartiles (Q2, Q3 and Q4) in the NAFLD group were 1.090 (0.978 to 1.215), 1.174 (1.055 to 1.305) and 1.152 (1.035 to 1.281), respectively, and age, gender, regular exercise, BMI, hypertension, TG, HDL-C, LDL-C and GLO (not smoking, hyperglycaemia, TC or ALB) were significant variables.
Table 4

HRs and their 95% CIs from the Cox model for prediction of NAFLD using WBC as the independent variable

UnadjustedModel 1*Model 2†Model 3‡
WBC count (cells×109/L)
 <5.35ReferenceReferenceReferenceReference
 5.35–6.201.310 (1.180 to 1.454)1.241 (1.118 to 1.378)1.243 (1.116 to 1.384)1.090 (0.978 to 1.215)
 6.20–7.141.511 (1.365 to 1.673)1.427 (1.289 to 1.580)1.440 (1.296 to 1.600)1.174 (1.055 to 1.305)
 ≥7.141.654 (1.497 to 1.828)1.507 (1.363 to 1.666)1.558 (1.404 to 1.729)1.152 (1.035 to 1.281)
Age1.019 (1.017 to 1.021)1.019 (1.017 to 1.021)1.007 (1.005 to 1.010)
Gender
 MaleReferenceReferenceReference
 Female0.618 (0.576 to 0.664)0.607 (0.563 to 0.654)0.746 (0.689 to 0.807)
Regular exercise0.922 (0.855 to 0.995)0.917 (0.850 to 0.989)
BMI1.153 (1.138 to 1.167)
Hypertension1.230 (1.126 to 1.344)
TG1.190 (1.165 to 1.216)
HDL-C0.798 (0.708 to 0.899)
LDL-C1.192 (1.134 to 1.253)
GLO1.011 (1.002 to 1.020)

*Adjusted by baseline age and gender.

†Adjusted by baseline age, gender, smoking and regular exercise.

‡Adjusted by baseline age, gender, smoking, regular exercise, BMI, hypertension, hyperglycaemia, TC, TG, HDL-C, LDL-C, ALB and GLO.

BMI, body mass index; GLO, globin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NAFLD, non-alcoholic fatty liver disease; TG, triglyceride; WBC, white blood cell count.

HRs and their 95% CIs from the Cox model for prediction of NAFLD using WBC as the independent variable *Adjusted by baseline age and gender. †Adjusted by baseline age, gender, smoking and regular exercise. ‡Adjusted by baseline age, gender, smoking, regular exercise, BMI, hypertension, hyperglycaemia, TC, TG, HDL-C, LDL-C, ALB and GLO. BMI, body mass index; GLO, globin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NAFLD, non-alcoholic fatty liver disease; TG, triglyceride; WBC, white blood cell count. Recently, Das et al27 has explored the association between haematological parameters and NAFLD. Our health check-up data showed that apart from WBC, that red blood cell count, haemoglobin, mean corpuscular volume, mean corpuscular haemoglobin concentration, red cell distribution width-SD (RDW-SD), neutrophil count and platelet count are also significantly associated with NAFLD (see online supplementary table S2).

Discussion

The effects of NAFLD were not limited to the liver but damaged various body systems; the extrahepatic damage was serious and increased the risk of CVD and diabetes.28 Consequently, it is very important to predict NAFLD and determine its risk factors. Some studies have reported that age is associated with NAFLD prevalence and that prevalence increases with age,29 30 as also seen in our study. The results in our study also show that NAFLD incidence is higher in males than in females (table 3), which was similar to previous studies.31–33 Lifestyle factors34 35 associated with NAFLD included smoking and physical activity. The baseline rate of regular exercise in the NAFLD group was significantly higher than that in the non-NAFLD group (p<0.001). This counter-intuitive finding may be partly due to the fact that other potential confounding factors (age, gender, BMI, hypertension, TG, HDL-C, LDL-C, GLO and smoking) were not adjusted for. However, the subsequent multivariate analysis showed regular exercise is indeed a protective factor against NAFLD. Additionally, and more importantly, a relationship between NAFLD and MS has been proposed in many studies which revealed that components of MS such as obesity, hypertension, dyslipidaemia and hyperglycaemia were independently associated with NAFLD.7 36 37 The results in our study also demonstrated that MS components were significantly different between individuals in the NAFLD and non-NAFLD groups (table 3), suggesting that NAFLD may be the liver manifestation of MS.38 39 Therefore, we explored the relationship between WBC and NAFLD after adjusting for age, gender, lifestyle factors and MS components. To our knowledge, only one cross-sectional study with Korean adults has shown a significant association between WBC count and NAFLD,22 which is consistent with our findings. Compared with the prospective cohort study, cross-sectional studies could not confirm the temporal association between WBC level and incident NAFLD. The results of cross-sectional studies can only provide markers for disease screening, not for disease prediction. WBC levels may not be a predictive factor for NAFLD unless confirmed in a cohort study. In this cohort study, we confirmed a relationship between WBC count and NAFLD incidence in urban Han Chinese (table 4), even if WBC changes were within the normal range. The relationship between WBC count and NAFLD remained valid after adjusting for other relevant factors including age, gender, smoking, regular exercise, BMI, hypertension, hyperglycaemia, TC, TG, HDL-C, LDL-C, ALB and GLO. The results prove that an elevated WBC level is related to NAFLD incidence, a finding which provides novel and powerful evidence for a significant relationship between WBC level and NAFLD. Thus, WBC count may be used as an independent predictor of NAFLD and is expected to improve prediction power when combined with other risk factors such as age, gender, BMI and hypertension status. The importance of WBC in subjects with only NAFLD may be different from that in those with NAFLD, cirrhosis and non-alcoholic steatohepatitis (NASH). Further study is required to elucidate these relationships. Moreover, some liver function test markers such as alanine aminotransferase (ALT), aspartate aminotransferase (AST) and γ-glutamyl transferase (GGT) should be explored in further study. This study suggests that inflammation plays an important role in the occurrence of NAFLD. Specifically, hepatic steatosis was the result of systemic inflammation, which is consistent with previous research. Many earlier studies have shown a significant association between CRP and NAFLD in Chilean Hispanic subjects,40 Asian Indians in North India,41 and Japanese42 and Korean individuals.43 These studies reported that elevated CRP was independently associated with the presence of NAFLD. Additionally, it was reported that serum TNF-α, IL-6 and interleukin-8 (IL-8) levels were higher in people with NAFLD than in normal subjects,44 45 indicating that these inflammatory factors are associated with the development of NAFLD. However, WBC is more suitable than inflammatory factors because it is a simple, readily available and inexpensive marker of inflammation for use in medical practice. There are two potential mechanisms for WBC participation in the onset of NAFLD.46 The first is insulin resistance which is the key factor associated with NAFLD. Insulin resistance causes TG synthesis and transport function disorders, and is a key mechanism in the development of MS. Indeed, NAFLD may be the liver manifestation of MS,9 39 47 as a relationship between WBC count and MS components has been documented in previous studies.48 49 This study showed significant changes in the components of MS with increasing WBC quartiles (table 2), suggesting insulin resistance may link WBC count and NAFLD. The second is the fact that hepatocytes with too much lipid are vulnerable to injurious processes such as cytokines and oxidative stress, which lead to inflammation and liver fibrosis.50 51 WBC count was frequently used to assess inflammatory status,52 and so was associated with NAFLD. Our study has several limitations. First, generalisability to the general population is unclear as the subjects in this study were recruited from a routine health check-up programme in an urban Han Chinese population in Shandong province. Consequently, further studies should be conducted to verify the relationship between WBC level and NAFLD in the general population. Second, the presence of NAFLD was assessed by experienced radiologists using abdominal ultrasonography, but we have no information on the intra- or inter-observer reliability of ultrasonographic examination. The diagnosis of NAFLD was not subjected to any semiquantitative indices.53 54 Ultrasonography is a well-established and cost-effective imaging technique for the diagnosis of hepatic steatosis, and is especially valuable for screening a large population at risk of NAFLD given that it is impossible to obtain the gold standard biopsy for large samples.55 Moreover, the severity of NAFLD is not stated clearly in the health check-up data so our results cannot be linked to NAFLD stage.
  54 in total

1.  A position statement on NAFLD/NASH based on the EASL 2009 special conference.

Authors:  Vlad Ratziu; Stefano Bellentani; Helena Cortez-Pinto; Chris Day; Giulio Marchesini
Journal:  J Hepatol       Date:  2010-05-07       Impact factor: 25.083

Review 2.  What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?

Authors:  Giovanni Tarantino; Carmine Finelli
Journal:  World J Gastroenterol       Date:  2013-06-14       Impact factor: 5.742

3.  Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.

Authors:  Iradj Maleki; Mahmood Reza Aminafshari; Tarang Taghvaei; Vahid Hosseini; Alireza Rafiei; Zhila Torabizadeh; Maryam Barzin; Elahe Orang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 4.  Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance.

Authors:  Mohamed Asrih; François R Jornayvaz
Journal:  J Endocrinol       Date:  2013-08-28       Impact factor: 4.286

5.  Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis.

Authors:  Rohit Loomba; Maria Abraham; Aynur Unalp; Laura Wilson; Joel Lavine; Ed Doo; Nathan M Bass
Journal:  Hepatology       Date:  2012-07-26       Impact factor: 17.425

6.  Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies.

Authors:  ZhanZhan Li; Jing Xue; Peng Chen; LiZhang Chen; ShiPeng Yan; LiYa Liu
Journal:  J Gastroenterol Hepatol       Date:  2014-01       Impact factor: 4.029

7.  Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

Authors:  Masahide Hamaguchi; Takao Kojima; Noriyuki Takeda; Chisato Nagata; Jun Takeda; Hiroshi Sarui; Yutaka Kawahito; Naohisa Yoshida; Atsushi Suetsugu; Takahiro Kato; Junichi Okuda; Kazunori Ida; Toshikazu Yoshikawa
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

8.  Differential white cell count and incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study.

Authors:  Carlos Lorenzo; Anthony J Hanley; Steven M Haffner
Journal:  Diabetologia       Date:  2013-10-19       Impact factor: 10.122

9.  Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units.

Authors:  Xiaona Hu; Yiqin Huang; Zhijun Bao; Yiqian Wang; Dongmei Shi; Fang Liu; Zhanjuan Gao; Xiaofeng Yu
Journal:  BMC Gastroenterol       Date:  2012-09-14       Impact factor: 3.067

10.  Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study.

Authors:  Ji Cheol Bae; Eun Jung Rhee; Won Young Lee; Se Eun Park; Cheol Young Park; Ki Won Oh; Sung Woo Park; Sun Woo Kim
Journal:  Diabetes Care       Date:  2011-01-28       Impact factor: 19.112

View more
  15 in total

1.  Sex-specific metabolic risk factors and their trajectories towards the non-alcoholic fatty liver disease incidence.

Authors:  C Tong; Q Li; L Kong; X Ni; A Halengbieke; S Zhang; Z Wu; L Tao; Y Han; D Zheng; X Guo; X Yang
Journal:  J Endocrinol Invest       Date:  2022-07-27       Impact factor: 5.467

Review 2.  Chronic Inflammation-A Link between Nonalcoholic Fatty Liver Disease (NAFLD) and Dysfunctional Adipose Tissue.

Authors:  Maria Petrescu; Sonia Irina Vlaicu; Lorena Ciumărnean; Mircea Vasile Milaciu; Codruța Mărginean; Mira Florea; Ștefan Cristian Vesa; Monica Popa
Journal:  Medicina (Kaunas)       Date:  2022-05-06       Impact factor: 2.948

3.  Inflammatory potential of diet and risk of nonalcoholic fatty liver disease: a prospective cohort study.

Authors:  Shunming Zhang; Ge Meng; Qing Zhang; Li Liu; Hongmei Wu; Yeqing Gu; Yawen Wang; Tingjing Zhang; Xuena Wang; Juanjuan Zhang; Shaomei Sun; Xing Wang; Ming Zhou; Qiyu Jia; Kun Song; Yaogang Wang; Lu Qi; Kaijun Niu
Journal:  Eur J Clin Nutr       Date:  2022-01-25       Impact factor: 4.884

4.  A predictive model for the diagnosis of non-alcoholic fatty liver disease based on an integrated machine learning method.

Authors:  Xuefeng Ma; Chao Yang; Kun Liang; Baokai Sun; Wenwen Jin; Lizhen Chen; Mengzhen Dong; Shousheng Liu; Yongning Xin; Likun Zhuang
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

Review 5.  Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets.

Authors:  Feliciano Chanana Paquissi
Journal:  Front Immunol       Date:  2016-11-11       Impact factor: 7.561

6.  Associations between White Blood Cell Count and the Development of Incidental Nonalcoholic Fatty Liver Disease.

Authors:  Goh Eun Chung; Jeong Yoon Yim; Donghee Kim; Min-Sun Kwak; Jong In Yang; Su Jin Chung; Sun Young Yang; Joo Sung Kim
Journal:  Gastroenterol Res Pract       Date:  2016-12-13       Impact factor: 2.260

7.  Nonalcoholic Fatty Liver Disease and Associated Metabolic Risks of Hypertension in Type 2 Diabetes: A Cross-Sectional Community-Based Study.

Authors:  Xiaoying Ding; Ying Xu; Yufan Wang; Xiaohua Li; Chunhua Lu; Jing Su; Yuhang Ma; Yuting Chen; Yanhua Yin; Lijun Zhang; Yong Wu; Yaqiong Jin; Lijun Zheng; Songmei Xu; Xiuli Zhu; Jilin Ma; Lihua Yu; Junyi Jiang; Naisi Zhao; Qingwu Yan; Andrew S Greenberg; Qianfang Huang; Qian Ren; Haiyan Sun; Mingyu Gu; Li Zhao; Yunhong Huang; Yijie Wu; Chunxian Qian; Yongde Peng
Journal:  Int J Endocrinol       Date:  2017-03-26       Impact factor: 3.257

8.  Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal.

Authors:  Bashu Dev Pardhe; Shreena Shakya; Anjeela Bhetwal; Jennifer Mathias; Puspa Raj Khanal; Roshan Pandit; Jyotsna Shakya; Hari Om Joshi; Sujan Babu Marahatta
Journal:  BMC Gastroenterol       Date:  2018-07-06       Impact factor: 3.067

9.  A binge high sucrose diet provokes systemic and cerebral inflammation in rats without inducing obesity.

Authors:  Omkar L Patkar; Abdalla Z Mohamed; Ashwin Narayanan; Karine Mardon; Gary Cowin; Rajiv Bhalla; Damion H R Stimson; Michael Kassiou; Kate Beecher; Arnauld Belmer; Ignatius Alvarez Cooper; Michael Morgan; David A Hume; Katharine M Irvine; Selena E Bartlett; Fatima Nasrallah; Paul Cumming
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

10.  Hematocrit Values Predict Carotid Intimal-Media Thickness in Obese Patients With Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study.

Authors:  Giovanni Tarantino; Luigi Barrea; Domenico Capone; Vincenzo Citro; Teresa Mosca; Silvia Savastano
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-30       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.